细胞免疫与基因治疗 

主旨演讲嘉宾 Plenary Speakers

首席执行官

复星凯特

(复星凯瑞 Fosun Kairos) 

演讲主题：Learnings in registration and commercialization as the pioneer in the China CAR-T market

Abstract:

Who is Fosun Kairos?

Fosun Kairos’ successful experience in registration and commercialization of YIKAIDA, the first CAR-T cell therapy in China;

Exploring innovative payment solutions to increase CAR-T accessibility;

Looking forward, how can we release the potential of China CGT market?

华坚

执董 总经理

上海医药集团生物治疗技术有限公司

上药生物治疗(香港)有限公司

演讲主题: 大药企背景下的细胞治疗布局

Speaker Bio: 

华坚，临床医学专业毕业，早年留学日本获管理硕士学位。回国后深耕医疗行业近20年，涉足生物医药、医疗器械、医学影像设备的研发、生产和销售等多个领域。此外，在香港创业板股权投资和房地产投融资等金融领域亦有十年从业经历，积累了丰富多元的跨行业经验。2018年底入职上海医药组建上药香港细胞治疗研发实验室，2019年组建上海医药上海细胞公司。现任上药生物治疗（香港）有限公司董事长、总经理，上海医药集团生物治疗有限公司执董、总经理，上海市肿瘤细胞治疗技术创新中心执行主任，上药与上海儿童医学中心合建儿童细胞治疗技术中心联合主任。

Mitchell Ho 何苗壮

美国国立卫生研究院 NIH

美国国立癌症研究所 NCI

终身资深研究员

美国肿瘤研究所抗体治疗研究室主任

演讲主题：Nanobody-Based CAR-T Cells Targeting Extracellular and Intracellular Tumor Antigens

Speaker Bio:

Dr. Ho is a Senior Investigator, the Deputy Chief of the Laboratory of Molecular Biology, the Head of the Antibody Therapy Section, and the Director of the Antibody Engineering Program at the National Cancer Institute (NCI), National Institutes of Health (NIH). He received his Ph.D. from the University of Illinois at Urbana-Champaign, where he generated anti-idiotypic antibodies as cocaine antagonists. He completed a postdoctoral fellowship at the NIH, where he engineered immunotoxins targeting CD22 and mesothelin for the treatment of B cell leukemias and mesothelioma. Dr. Ho has pioneered the generation of therapeutic antibodies that target cancer-associated heparan sulfate proteoglycans. A focus of his laboratory work is on the validation of cell surface glypicans such as GPC3, GPC2 and GPC1 as new therapeutic targets in cancer. This area of research ranges from investigation of the fundamental mechanisms by which glypicans regulate Wnt, Yap and other signaling molecules to the design of antibody-based cancer therapeutics. His laboratory also established mammalian cell surface display, developed rabbit monoclonal antibodies, and built shark and camel single domain antibody phage libraries as new tools to advance antibody engineering and drug discovery. The immune therapeutics such as CAR-T cells based on his research are being tested at clinical stages for treating liver cancer, neuroblastoma, mesothelioma and other cancers.

Dr. Ho is was elected to the Board of Directors for the Antibody Society and to the Board of Directors for the Foundation for Advanced Education in the Sciences (FAES). Dr. Ho received many awards including the Asian & Pacific Islander American Organization (APAO) Scientific Achievement Award, Dr. Francisco S. Sy Award for Excellence in Mentorship at HHS, NIH Deputy Director for Intramural Research (DDIR) Innovation Award, and NCI Director’s Innovation Award.

.........